COMMUNIQUÉS West-GlobeNewswire

Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
13/04/2026
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is based on data from the [...]
Communiqué de presse : Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants
13/04/2026
Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants L'approbation dans l'urticaire chronique spontanée (UCS) pour les enfants [...]
Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis
13/04/2026
The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis. 1 This minimally invasive blood test enables greater patient [...]
Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
13/04/2026
BASEL, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- BioVersys and partners publish in the prestigious journal of Nature Communications pre-clinical development data of AlpE (alpibectir and ethionamide), an innovative [...]
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
13/04/2026
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria [...]
Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
13/04/2026
NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to receive US [...]
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
11/04/2026
Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer [...]
NeuroSalt Under Investigation: What the 2026 Formulation Transparency Review Reveals About Botanical Ingredients, Dosage Disclosure, and Consumer Verification
11/04/2026
A detailed overview of NeuroSalt's five-ingredient plant-based nerve health supplement — covering botanical formula composition, ingredient-level research, dosage disclosure, 60-day refund policy, and the consumer [...]
Gentle Patches Claims Evaluated: 2026 Consumer Interest Rises Around Transdermal Wellness Patch Ingredients, Product Lineup, and Policy Transparency
11/04/2026
A timely 2026 release highlighting growing consumer research interest in skin-absorption wellness formats, ingredient themes, product variety, and publicly visible brand information across the Gentle Patches pill-free [...]
Glo & Spa-rkle Aesthetics and Medical Spa Unveils New State-of-the-Art Location in Lubbock, Texas
11/04/2026
Join the Grand Opening Celebration on May 1, 2026, for an Evening of Beauty and Innovation Lubbock, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Glo & Spa-rkle Aesthetics and Medical Spa , a leader in aesthetic and [...]
IVY Rx Claims Evaluated: 2026 Compounded GLP-1 Telehealth Program Details, Monthly Pricing Structure, Clinician Access Model, and Patient Eligibility Information
11/04/2026
New 2026 program information covers self-pay pricing tiers, HSA/FSA eligibility, compounded semaglutide and tirzepatide access, three-entity telehealth structure, and key considerations for prospective patients [...]
ReadyRx NAD+ Rx Claims Evaluated: 2026 Update Highlights Changes in Prescription NAD+ Nasal Spray and Injection Access, Pricing, and Telehealth Eligibility
10/04/2026
New 2026 Program Overview Details Compounded NAD+ Therapy Access, Three-Entity Telehealth Structure, and What Patients Should Know Before Starting Clinician-Reviewed Prescription NAD+ Programs Cheyenne, WY, April 10, [...]
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
10/04/2026
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the [...]
Pelthos Therapeutics Announces CFO Transition
10/04/2026
Senior Vice President, Finance & Accounting John M. Gay named Chief Financial Officer DURHAM, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/04/2026
BRISBANE, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on April 8, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera [...]
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
10/04/2026
Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children are living with DMD in the U.S. NEW YORK, April 10, 2026 (GLOBE NEWSWIRE [...]
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/04/2026
CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent [...]
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
10/04/2026
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
10/04/2026
SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for [...]

Pages